BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 28, 2010
View Archived Issues
YM Could Bring in Up to $7.75M in Controlled Equity Financing
Read More
Biotie Goes Partner Hunting After Roche Pulls Out of Mab Project
Read More
Adventrx Plunges on Delay in Cancer Drug Resubmission
Read More
Come See Us at BIO 2010 And Get Your Chicago Hat
Read More
Other News To Note
Read More
Stock Movers
Read More
Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data
Impressive, though early stage, Phase I data already has Pluristem Therapeutics Inc. setting the stage for Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. (BioWorld Today)
Read More
AB Science Brings in €27.5M After Scaling Back its IPO
No Abstract
Read More
Clinic Roundup
Read More